Current and historical daily PE Ratio for Daiichi Sankyo Co Ltd (
FRA:D4S
) from 2005 to May 05 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Daiichinkyo stock (FRA:D4S) PE ratio as of May 05 2024 is 47.89.
More Details
Daiichi Sankyo Co Ltd (FRA:D4S) PE Ratio (TTM) Chart
Daiichi Sankyo Co Ltd (FRA:D4S) PE Ratio (TTM) Historical Data
View and export this data going back to 2005. Start your Free Trial
Total 1232
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Daiichinkyo PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-05 | 49.5 | 2024-02-28 | 48.5 |
| 2024-05-03 | 49.5 | 2024-02-27 | 50.7 |
| 2024-05-02 | 50.5 | 2024-02-26 | 49.1 |
| 2024-04-30 | 48.6 | 2024-02-23 | 48.7 |
| 2024-04-29 | 45.6 | 2024-02-22 | 48.6 |
| 2024-04-26 | 44.1 | 2024-02-21 | 49.0 |
| 2024-04-25 | 44.0 | 2024-02-20 | 49.1 |
| 2024-04-24 | 42.6 | 2024-02-19 | 52.7 |
| 2024-04-23 | 41.7 | 2024-02-16 | 48.6 |
| 2024-04-22 | 41.6 | 2024-02-15 | 46.6 |
| 2024-04-19 | 43.0 | 2024-02-14 | 46.5 |
| 2024-04-18 | 40.8 | 2024-02-13 | 45.7 |
| 2024-04-17 | 40.8 | 2024-02-12 | 45.1 |
| 2024-04-16 | 41.0 | 2024-02-09 | 46.7 |
| 2024-04-15 | 41.1 | 2024-02-08 | 45.7 |
| 2024-04-12 | 43.3 | 2024-02-07 | 44.4 |
| 2024-04-11 | 40.8 | 2024-02-06 | 44.3 |
| 2024-04-10 | 42.0 | 2024-02-05 | 44.9 |
| 2024-04-09 | 42.0 | 2024-02-02 | 44.2 |
| 2024-04-08 | 42.0 | 2024-02-01 | 45.9 |
| 2024-04-05 | 42.1 | 2024-01-31 | 43.3 |
| 2024-04-04 | 42.6 | 2024-01-30 | 42.8 |
| 2024-04-03 | 42.4 | 2024-01-29 | 42.5 |
| 2024-04-02 | 43.4 | 2024-01-26 | 41.9 |
| 2024-03-28 | 44.7 | 2024-01-25 | 41.9 |
| 2024-03-27 | 47.4 | 2024-01-24 | 42.4 |
| 2024-03-26 | 46.1 | 2024-01-23 | 43.1 |
| 2024-03-25 | 46.1 | 2024-01-22 | 42.6 |
| 2024-03-22 | 48.3 | 2024-01-19 | 42.2 |
| 2024-03-21 | 46.6 | 2024-01-18 | 42.3 |
| 2024-03-20 | 46.5 | 2024-01-17 | 42.5 |
| 2024-03-19 | 46.9 | 2024-01-16 | 44.7 |
| 2024-03-18 | 47.6 | 2024-01-12 | 44.6 |
| 2024-03-15 | 46.8 | 2024-01-11 | 45.1 |
| 2024-03-14 | 45.5 | 2024-01-10 | 42.8 |
| 2024-03-13 | 44.9 | 2024-01-09 | 40.2 |
| 2024-03-12 | 46.3 | 2024-01-08 | 41.1 |
| 2024-03-11 | 47.1 | 2024-01-05 | 41.1 |
| 2024-03-08 | 48.1 | 2024-01-04 | 39.8 |
| 2024-03-07 | 47.6 | 2024-01-03 | 39.0 |
| 2024-03-06 | 47.5 | 2024-01-02 | 38.9 |
| 2024-03-05 | 47.6 | 2023-12-29 | 38.8 |
| 2024-03-04 | 48.4 | 2023-12-28 | 38.7 |
| 2024-03-01 | 48.2 | 2023-12-27 | 47.0 |
| 2024-02-29 | 48.0 | 2023-12-22 | 47.1 |
Daiichi Sankyo Co Ltd (FRA:D4S) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Daiichi Sankyo Co Ltd
ISIN : JP3475350009
Description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers